Literature DB >> 1310353

Clinical outcome in aggressively treated meningeal gliomatosis.

R Grant1, B Naylor, L Junck, H S Greenberg.   

Abstract

We reviewed 11 consecutive patients with an antemortem cytologic diagnosis of meningeal gliomatosis. In three patients, meningeal gliomatosis was diagnosed before surgical resection of the glioma. Three of five patients with anaplastic astrocytoma and one with oligodendroglioma improved with treatment. Patients with glioblastoma multiforme did not respond and had a median survival from the diagnosis of meningeal gliomatosis of only 8 weeks. Meningeal gliomatosis can be an early finding in gliomas. Treatment response is probably related to tumor histology and grade.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310353     DOI: 10.1212/wnl.42.1.252

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Treatment of meningeal gliomatosis.

Authors:  P F Pradat; K Hoang-Xuan; P Cornu; K Mokhtari; N Martin-Duverneuil; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

Review 2.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.

Authors:  Matthew K Knox; Cynthia Ménard; Warren P Mason
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

4.  Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.

Authors:  Fulin Wang; Guangyu Qiao; Xin Lou
Journal:  J Neurooncol       Date:  2010-12-29       Impact factor: 4.130

5.  PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.

Authors:  S Izumoto; T Ohnishi; H Kanemura; N Arita; M Maruno; T Moriuchi; S Suzuki; T Yoshimine
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.